Charles Thomas

Charles's expertise in biotechnology, medicine, and biochemistry extends from his years of experience in both industry and academia. As a research associate at a biotech company, he was integral to the development of vector-based therapeutics for ocular diseases and vaccines for malaria. In his graduate work, Charles appropriated molecular biology and embryonic cell culture techniques to elucidate mechanisms of intrinsic neuroinflammation in the rare pediatric disorder Aicardi-Goutières Syndrome.  His work led to a discovery of several FDA-approved medications that could be repurposed to treat affected patients. Throughout the years, Charles’s research has been published in a number of top-tier journals, including Cell Stem Cell, Annual Review of Cell and Developmental Biology, Journal of Virology, and Molecular Therapy.

Charles has established a practice that focuses on prosecution of emerging technologies in the various fields of biology and chemistry, including therapeutic discovery, immunology, cytometry, cell culture, molecular biology, bioinformatics, recombinant biology, and small molecule chemistry. Through detailed communications and diligent effort, Charles strives to provide the most robust patent protection for his clients.

Patent Protection

Virginia Tech, B.S., Biochemistry; B.S., Biology; B.A., Chemistry, summa cum laude
University of California, San Diego, Ph.D., Biomedical Sciences
University of Southern California, Gould School of Law, J.D.

California State Bar
United States Patent and Trademark Office

Thomas, C.A. et al. Modeling of TREX1-Dependent Autoimmune Disease using Human Stem Cells Highlights L1 Accumulation as a Source of Neuroinflammation. Cell Stem Cell. 2017 (

Thomas, C.A., Paquola, A.C., & Muotri, A.R. LINE-1 Retrotransposition in the Nervous System. Annu. Rev. Cell Dev. Biol. 2012; 28:555-73. (